Arcus Biosciences Inc Total Liabilities
Arcus Biosciences Inc total liabilities. Based on the latest financial reports, Arcus Biosciences Inc (RCUS) has total liabilities worth $473.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Arcus Biosciences Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Arcus Biosciences Inc (2016–2025)
Total liabilities of Arcus Biosciences Inc from 2016 to 2025. This chart illustrates how Arcus Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore RCUS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Arcus Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Arcus Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Aeroméxico, S.A.B. de C.V.
NYSE:AERO
|
USA | $8.02 Billion |
|
Lakala Payment Co Ltd
SHE:300773
|
China | CN¥5.81 Billion |
|
SOC.BIC UNS.ADR1/2/EO382
F:BIF0
|
Germany | €1.06 Billion |
|
CSG Systems International Inc
NASDAQ:CSGS
|
USA | $1.19 Billion |
|
Slide Insurance Holdings, Inc. Common Stock
NASDAQ:SLDE
|
USA | $1.72 Billion |
|
Liveramp Holdings Inc
NYSE:RAMP
|
USA | $301.41 Million |
|
Henan Huanghe Whirlwind Co Ltd
SHG:600172
|
China | CN¥6.74 Billion |
|
Grindwell Norton Limited
NSE:GRINDWELL
|
India | Rs8.45 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Arcus Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Arcus Biosciences Inc asset portfolio.
Liquidity & Leverage Metrics
Arcus Biosciences Inc Total Liabilities Ratios Explained
Arcus Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arcus Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arcus Biosciences Inc (2016–2025)
The table below shows the annual total liabilities of Arcus Biosciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $508.00 Million | -23.61% |
| 2024-12-31 | $665.00 Million | +5.06% |
| 2023-12-31 | $633.00 Million | -7.99% |
| 2022-12-31 | $688.00 Million | -8.32% |
| 2021-12-31 | $750.45 Million | +177.96% |
| 2020-12-31 | $269.99 Million | +587.55% |
| 2019-12-31 | $39.27 Million | -1.79% |
| 2018-12-31 | $39.98 Million | +9.19% |
| 2017-12-31 | $36.62 Million | +257.53% |
| 2016-12-31 | $10.24 Million | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, a… Read more